Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BRAF V600E PDGFRB over exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E PDGFRB over exp | melanoma | sensitive | XL888 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with XL888 increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant human melanoma cell lines harboring a BRAF V600E mutation and over expression of PDGFRB in cell culture and in xenograft models (PMID: 22351686). | 22351686 | |
| BRAF V600E PDGFRB over exp | melanoma | resistant | Vemurafenib | Preclinical | Actionable | In a preclinical study, over expression of PDGFRB conferred acquired resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323). | 21107323 | |
| BRAF V600E PDGFRB over exp | melanoma | resistant | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line harboring BRAF V600E and overexpressing Pdgfrb demonstrated resistance to Mekinist (trametinib) in culture (PMID: 28986383). | 28986383 | |
| BRAF V600E PDGFRB over exp | melanoma | resistant | Vemurafenib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line harboring BRAF V600E and overexpressing Pdgfrb demonstrated resistance to Zelboraf (vemurafenib) in culture (PMID: 28986383). | 28986383 |